Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma | Prof Grant McArthur

Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma | Prof Grant McArthur

EMJ

4 years
393 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia, discusses the impact of baseline genetic heterogeneities on progression-free survival in patients with advanced BRAF V600-mutated melanoma treated with cobimetinib plus vemurafenib in the phase 3 coBRIM clinical trial. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay